EWS-FLI1 t(11;22)(q24;q12) Type 1 or Type 2 Translocation (RT-PCR) (DISCONTINUED)

Specimen Container

-

Specimen Requirement

1. Formalin-Fixed Paraffin-Embedded block or
2. 10x unstained sections and 1 corresponding H&E slide.

Tissue must be non-necrotic, non-cauterised, and must not have undergone acid-based decalcification. Improper storage conditions may additionally compromise nucleic acid integrity.

Specimen Storage / Transport

Method

Orderable as STAT?

No

Turn Around Time

7 Working days

Reference Value(s)

Testing Laboratory Location

KKH

Laboratory

Molecular Histopathology

Contact Number

6394 1402

Day and Time Performed

Mon – Fri: 0800 hrs– 1700 hrs

Orderable on CPOE?

Yes

Downtime Form

Molecular Histopathology

Additional Information

Ewing tumours form a histologically heterogeneous family belonging to the group of small round-cell tumours and derived from neural crests cells. Ewing’s sarcoma represents 5 to 15% of malignant bone and soft tissue tumours. About 90% of Ewing’s tumours show a t(11;22)(q24;q12); the translocation results in the fusion of the EWS gene with the transcription factor gene FLI1, leading to a hybrid transcript and an oncogenic chimeric protein. The Type 1 translocation has a different clinical prognosis than Type 2 translocation. Our real-time RT-PCR assay identifies both the FLI1t(11;22)(q24;q12) Type 1 and Type 2 translocations.

Expected Test Result:

EWS-FLI1 type 1/2 fusion is detected/not detected (RNA integrity is acceptable as checked by housekeeping gene)/ The assay is inconclusive (RNA quality is not good enough)

The molecular test result must always be correlated with clinical and histopathological findings by an appropriately trained, qualified and experienced pathologist.

Quality Assurance: CAP (SARC)

HT0201